Moderna sees revenue bump from international COVID vaccine sales
Summary
The company is making up for a decline in U.S. vaccine sales with better results elsewhere, continuing a turnaround that’s vaulted its stock price in 2026.
Original reporting
Open original sourceAFBytes is a read-only aggregator. Use the original source for full context and complete reporting.